Posted On: 08/17/2016 3:27:28 AM
Post# of 273351
Mymetics Corp (MYMX) 0.0152 $MYMX
Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute
Marketwired - Mon Apr 11, 2:01AM CDT
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
Mymetics Announces Successful Preclinical Results With Malaria Transmission-Blocking Vaccine Candidate
Marketwire Canada - Tue Apr 05, 1:32AM CDT
Mymetics Corporation (OTCQB:MYMX), a pioneer in the research and development of virosome based vaccines to prevent transmission of human infectious diseases, announced today that the preclinical study with Mymetics' virosome based formulations for a malaria transmission-blocking vaccine candidate has been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.
Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 7.14 (-0.13), FOMX: 8.60 (-0.06), GNCA: 5.39 (+0.08), NNVC: 1.70 (+0.01)
Mymetics Announces Discontinuation of the RSV Collaborative Project
Marketwired - Thu Jan 28, 9:01PM CST
Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Bestewil Holding BV, has received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. On December 27, 2013, Mymetics and RSVC, funded by Astellas Pharma Inc., had announced the signature of a License and Collaboration Agreement focusing on RSV, which will now formally be terminated as of July 25, 2016.
Global Herpes Labialis (Oral Herpes) Therapeutics Pipeline Report 2015
M2 - Fri Jan 22, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvt8qz/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Herpes Labialis (Oral Herpes) Overview - Therapeutics Development - Pipeline Products for Herpes Labialis (Oral Herpes) - Overview - Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis - Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies - Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes - Herpes Labialis (Oral Herpes) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Herpes Labialis (Oral Herpes) - Products under Development by Companies - Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes - Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development - Beech Tree Labs, Inc. - Foamix Pharmaceuticals Ltd. - Mymetics Corporation - NanoViricides, Inc. - Onxeo SA - Shulov Innovative Science Ltd. - TGV-Laboratories For more information visit http://www.researchandmarkets.com/research/tv...s_labialis
FOMX: 8.60 (-0.06), NNVC: 1.70 (+0.01)
Global Genital Herpes Pipeline Review 2015 - 19 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqbrzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Admedus Ltd - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - PaxVax - Profectus BioSciences, Inc. - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS - Vaxart, Inc. - Vical Incorporated Drug Profiles - acyclovir - Aspidasept - astodrimer - G-103 - GEN-002 - GEN-003 - genital herpes vaccine [HSV-2] - GV-2207 - HerpeCide-I - herpes simplex virus [serotype 2] vaccine - herpes simplex virus [type 1, 2] vaccine - HSV-529 - pritelivir - SB-105A10 - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/hq...tal_herpes
VICL: 4.35 (-0.05), IMDZ: 7.14 (-0.13), FOMX: 8.60 (-0.06), GNCA: 5.39 (+0.08), NNVC: 1.70 (+0.01)
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4lpfw/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Beech Tree Labs, Inc. - Foamix Pharmaceuticals Ltd. - Mymetics Corporation - NanoViricides, Inc. - Onxeo SA - Spider Biotech For more information visit http://www.researchandmarkets.com/research/q4...s_labialis
FOMX: 8.60 (-0.06), NNVC: 1.70 (+0.01)
Oral Herpes (Herpes Labialis) Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Mon Jun 22, 2:04AM CDT
The report "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes). The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. A complete report on Herpes Labialis (Oral Herpes) with 21 market data tables and 13 figures, spread across 43 pages is available at http://www.rnrmarketresearch.com/herpes-labia...eport.html .
FOMX: 8.60 (-0.06), NNVC: 1.70 (+0.01)
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 7.14 (-0.13), CVM: 0.51 (+0.01), FOMX: 8.60 (-0.06), ADMP: 2.57 (-0.08), GNCA: 5.39 (+0.08), NNVC: 1.70 (+0.01), CMRX: 4.51 (-0.15)
Mymetics-led Consortium Awarded Euro 8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines
ACCESSWIRE - Mon Apr 20, 1:01AM CDT
- Mymetics virosome vaccine technology and HIV vaccine candidate to be used as basis to develop a scalable manufacturing process within 3.5 years
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.51 (+0.01), PFNX: 9.77 (-0.74), INO: 8.76 (-0.12), CMRX: 4.51 (-0.15), RPTP: 6.53 (-0.26), IBIO: 0.65 (-0.01), ANAC: 99.06 (-0.14), PFE: 34.79 (-0.32), GNCA: 5.39 (+0.08), GSK: 44.32 (-0.08), AZN: 33.55 (+0.11), NVS: 81.77 (-0.57)
Mymetics Announces New Collaboration to Advance the Development of an Innovative Malaria Vaccine Candidate
Marketwired - Wed Nov 19, 3:27PM CST
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 7.14 (-0.13), CMRX: 4.51 (-0.15), CVM: 0.51 (+0.01), ADMP: 2.57 (-0.08), GNCA: 5.39 (+0.08)
Mymetics' HIV Vaccine Candidate Confirms Promise in Preclinical Study With the Texas Biomedical Research Institute
Marketwired - Mon Apr 11, 2:01AM CDT
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
Mymetics Announces Successful Preclinical Results With Malaria Transmission-Blocking Vaccine Candidate
Marketwire Canada - Tue Apr 05, 1:32AM CDT
Mymetics Corporation (OTCQB:MYMX), a pioneer in the research and development of virosome based vaccines to prevent transmission of human infectious diseases, announced today that the preclinical study with Mymetics' virosome based formulations for a malaria transmission-blocking vaccine candidate has been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.
Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 7.14 (-0.13), FOMX: 8.60 (-0.06), GNCA: 5.39 (+0.08), NNVC: 1.70 (+0.01)
Mymetics Announces Discontinuation of the RSV Collaborative Project
Marketwired - Thu Jan 28, 9:01PM CST
Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that its subsidiary Bestewil Holding BV, has received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. On December 27, 2013, Mymetics and RSVC, funded by Astellas Pharma Inc., had announced the signature of a License and Collaboration Agreement focusing on RSV, which will now formally be terminated as of July 25, 2016.
Global Herpes Labialis (Oral Herpes) Therapeutics Pipeline Report 2015
M2 - Fri Jan 22, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvt8qz/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Herpes Labialis (Oral Herpes) Overview - Therapeutics Development - Pipeline Products for Herpes Labialis (Oral Herpes) - Overview - Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis - Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies - Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes - Herpes Labialis (Oral Herpes) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Herpes Labialis (Oral Herpes) - Products under Development by Companies - Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes - Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development - Beech Tree Labs, Inc. - Foamix Pharmaceuticals Ltd. - Mymetics Corporation - NanoViricides, Inc. - Onxeo SA - Shulov Innovative Science Ltd. - TGV-Laboratories For more information visit http://www.researchandmarkets.com/research/tv...s_labialis
FOMX: 8.60 (-0.06), NNVC: 1.70 (+0.01)
Global Genital Herpes Pipeline Review 2015 - 19 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqbrzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Admedus Ltd - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - PaxVax - Profectus BioSciences, Inc. - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS - Vaxart, Inc. - Vical Incorporated Drug Profiles - acyclovir - Aspidasept - astodrimer - G-103 - GEN-002 - GEN-003 - genital herpes vaccine [HSV-2] - GV-2207 - HerpeCide-I - herpes simplex virus [serotype 2] vaccine - herpes simplex virus [type 1, 2] vaccine - HSV-529 - pritelivir - SB-105A10 - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/hq...tal_herpes
VICL: 4.35 (-0.05), IMDZ: 7.14 (-0.13), FOMX: 8.60 (-0.06), GNCA: 5.39 (+0.08), NNVC: 1.70 (+0.01)
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4lpfw/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Beech Tree Labs, Inc. - Foamix Pharmaceuticals Ltd. - Mymetics Corporation - NanoViricides, Inc. - Onxeo SA - Spider Biotech For more information visit http://www.researchandmarkets.com/research/q4...s_labialis
FOMX: 8.60 (-0.06), NNVC: 1.70 (+0.01)
Oral Herpes (Herpes Labialis) Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Mon Jun 22, 2:04AM CDT
The report "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes). The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. A complete report on Herpes Labialis (Oral Herpes) with 21 market data tables and 13 figures, spread across 43 pages is available at http://www.rnrmarketresearch.com/herpes-labia...eport.html .
FOMX: 8.60 (-0.06), NNVC: 1.70 (+0.01)
Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 7.14 (-0.13), CVM: 0.51 (+0.01), FOMX: 8.60 (-0.06), ADMP: 2.57 (-0.08), GNCA: 5.39 (+0.08), NNVC: 1.70 (+0.01), CMRX: 4.51 (-0.15)
Mymetics-led Consortium Awarded Euro 8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines
ACCESSWIRE - Mon Apr 20, 1:01AM CDT
- Mymetics virosome vaccine technology and HIV vaccine candidate to be used as basis to develop a scalable manufacturing process within 3.5 years
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.51 (+0.01), PFNX: 9.77 (-0.74), INO: 8.76 (-0.12), CMRX: 4.51 (-0.15), RPTP: 6.53 (-0.26), IBIO: 0.65 (-0.01), ANAC: 99.06 (-0.14), PFE: 34.79 (-0.32), GNCA: 5.39 (+0.08), GSK: 44.32 (-0.08), AZN: 33.55 (+0.11), NVS: 81.77 (-0.57)
Mymetics Announces New Collaboration to Advance the Development of an Innovative Malaria Vaccine Candidate
Marketwired - Wed Nov 19, 3:27PM CST
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has chosen Mymetics to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate. MVI is a global program whose objective is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries.
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 7.14 (-0.13), CMRX: 4.51 (-0.15), CVM: 0.51 (+0.01), ADMP: 2.57 (-0.08), GNCA: 5.39 (+0.08)
(0)
(0)
